Dashboard
Manage Tickers

RAPT


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

ubs-maintains-neutral-on-rapt-therapeutics-lowers-price-target-to-2
UBS Maintains Neutral on RAPT Therapeutics...
09/09/2024 14:23:09

UBS analyst Eliana Merle maintains RAPT Therapeutics (NASDAQ:RAPT) with a Neutral and lowers the price target from $10 to $2.

hc-wainwright--co-reiterates-neutral-on-rapt-therapeutics
HC Wainwright & Co. Reiterates Neutral on ...
08/20/2024 11:16:57

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates RAPT Therapeutics (NASDAQ:RAPT) with a Neutral.

rapt-therapeutics-q2-eps-071-beats-072-estimate
RAPT Therapeutics Q2 EPS $(0.71) Beats $(0...
08/08/2024 12:27:33

RAPT Therapeutics (NASDAQ:RAPT) reported quarterly losses of $(0.71) per share which beat the analyst consensus estimate of $(0...

hc-wainwright--co-reiterates-neutral-on-rapt-therapeutics
HC Wainwright & Co. Reiterates Neutral on ...
07/23/2024 11:20:46

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates RAPT Therapeutics (NASDAQ:RAPT) with a Neutral.

rapt-therapeutics-will-reduce-its-workforce-by-47-people-or-approximately-40-of-its-existing-headcount-the-company-estimates-that-it-will-incur-approximately-09m-in-restructuring-charges-8k
Rapt Therapeutics Will Reduce Its Workforc...
07/22/2024 12:05:37

12-health-care-stocks-moving-in-mondays-after-market-session
12 Health Care Stocks Moving In Monday's A...
06/03/2024 20:31:11

top-5-health-care-stocks-which-could-rescue-your-portfolio-this-month
Top 5 Health Care Stocks Which Could Rescu...
05/21/2024 12:39:25

wolfe-research-downgrades-rapt-therapeutics-to-peer-perform
Wolfe Research Downgrades RAPT Therapeutic...
05/14/2024 12:01:08

Wolfe Research analyst Andy Chen downgrades RAPT Therapeutics (NASDAQ:RAPT) from Outperform to Peer Perform.

barclays-downgrades-rapt-therapeutics-to-equal-weight-lowers-price-target-to-4
Barclays Downgrades RAPT Therapeutics to E...
05/10/2024 13:21:00

Barclays analyst Leon Wang downgrades RAPT Therapeutics (NASDAQ:RAPT) from Overweight to Equal-Weight and lowers the price t...

guggenheim-downgrades-rapt-therapeutics-to-neutral
Guggenheim Downgrades RAPT Therapeutics to...
05/10/2024 10:29:15

Guggenheim analyst Yatin Suneja downgrades RAPT Therapeutics (NASDAQ:RAPT) from Buy to Neutral.

whats-going-on-with-dermatitis-focused-rapt-therapeutics-stock-on-thursday
What's Going On With Dermatitis-Focused RA...
05/09/2024 18:12:49

RAPT Therapeutics closes Phase 2 trials for zelnecirnon in atopic dermatitis & asthma following FDA clinical hold due to li...

why-duolingo-shares-are-trading-lower-by-around-18-here-are-other-stocks-moving-in-thursdays-mid-day-session
Why Duolingo Shares Are Trading Lower By A...
05/09/2024 17:57:05

12-health-care-stocks-moving-in-thursdays-intraday-session
12 Health Care Stocks Moving In Thursday's...
05/09/2024 16:31:09

rapt-therapeutics-q1-eps-079-beats-081-estimate
RAPT Therapeutics Q1 EPS $(0.79) Beats $(0...
05/09/2024 13:01:31

RAPT Therapeutics (NASDAQ:RAPT) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of $(0...

hc-wainwright--co-reiterates-neutral-on-rapt-therapeutics
HC Wainwright & Co. Reiterates Neutral on ...
04/10/2024 10:19:57

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates RAPT Therapeutics (NASDAQ:RAPT) with a Neutral.

rapt-therapeutics-highlights-results-from-phase-2-trial-of-tivumecirnon-in-combination-with-anti-pd-1-immunotherapy-in-cpi-experienced-head-and-neck-cancer-patients
RAPT Therapeutics Highlights Results From ...
04/09/2024 16:01:38

- Confirmed objective response rate (ORR) of 15.6% in all patients regardless of PD-L1 or HPV status - Confirmed ORR of 17.4% i...

jp-morgan-maintains-neutral-on-rapt-therapeutics-lowers-price-target-to-13
JP Morgan Maintains Neutral on RAPT Therap...
03/27/2024 14:44:03

JP Morgan analyst Anupam Rama maintains RAPT Therapeutics (NASDAQ:RAPT) with a Neutral and lowers the price target from $15 ...

rapt-therapeutics-q4-earnings-insights
RAPT Therapeutics: Q4 Earnings Insights
03/07/2024 14:25:06

rapt-therapeutics-q4-eps-080-beats-086-estimate-cash-balance-of-1589m-as-of-december-31-2023
RAPT Therapeutics Q4 EPS $(0.80) Beats $(0...
03/07/2024 13:06:20

RAPT Therapeutics (NASDAQ:RAPT) reported quarterly losses of $(0.80) per share which beat the analyst consensus estimate of $(0...

rapt-therapeutics-announces-multiple-late-breaking-presentations-at-the-upcoming-american-association-for-cancer-research-annual-meeting
RAPT Therapeutics Announces Multiple Late-...
03/05/2024 21:34:13

RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developi...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION